局部露立康唑治疗角化性足癣。

IF 2.9 3区生物学 Q2 MYCOLOGY

Mycopathologia Pub Date : 2025-07-23 DOI:10.1007/s11046-025-00977-z

Sayaka Ohara, Hiromitsu Noguchi, Tadahiko Matsumoto, Daiki Hayashi, Kayo Kashiwada-Nakamura, Masahide Kubo, Rui Kano, Satoshi Fukushima

{"title":"局部露立康唑治疗角化性足癣。","authors":"Sayaka Ohara, Hiromitsu Noguchi, Tadahiko Matsumoto, Daiki Hayashi, Kayo Kashiwada-Nakamura, Masahide Kubo, Rui Kano, Satoshi Fukushima","doi":"10.1007/s11046-025-00977-z","DOIUrl":null,"url":null,"abstract":"Chronic hyperkeratotic tinea pedis is a treatment-resistant infection. We evaluated the efficacy of a 3-month course of topical 1% luliconazole in 21 hyperkeratotic tinea pedis patients. The diagnosis was confirmed through microscopy and culture. The lesion area was assessed monthly using a software program. Clinical responses were classified into five categories from \"cured\" to \"no change.\" Among the isolates, one terbinafine-resistant T. rubrum strain was detected. The mean lesion area decreased significantly over 3 months, with an average improvement rate of 94.1% ± 12.7% and a cure rate of 61.9%. The mean amount of luliconazole used per foot was 27.5 ± 9.7 g monthly. The resistant case showed a partial improvement with topical luliconazole and was successfully treated with oral fosravuconazole. These findings suggest that 1% topical luliconazole is effective for treating hyperkeratotic tinea pedis.","PeriodicalId":19017,"journal":{"name":"Mycopathologia","volume":"190 5","pages":"66"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Topical Luliconazole Treatment for Hyperkeratotic Tinea Pedis.\",\"authors\":\"Sayaka Ohara, Hiromitsu Noguchi, Tadahiko Matsumoto, Daiki Hayashi, Kayo Kashiwada-Nakamura, Masahide Kubo, Rui Kano, Satoshi Fukushima\",\"doi\":\"10.1007/s11046-025-00977-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic hyperkeratotic tinea pedis is a treatment-resistant infection. We evaluated the efficacy of a 3-month course of topical 1% luliconazole in 21 hyperkeratotic tinea pedis patients. The diagnosis was confirmed through microscopy and culture. The lesion area was assessed monthly using a software program. Clinical responses were classified into five categories from \\\"cured\\\" to \\\"no change.\\\" Among the isolates, one terbinafine-resistant T. rubrum strain was detected. The mean lesion area decreased significantly over 3 months, with an average improvement rate of 94.1% ± 12.7% and a cure rate of 61.9%. The mean amount of luliconazole used per foot was 27.5 ± 9.7 g monthly. The resistant case showed a partial improvement with topical luliconazole and was successfully treated with oral fosravuconazole. These findings suggest that 1% topical luliconazole is effective for treating hyperkeratotic tinea pedis.\",\"PeriodicalId\":19017,\"journal\":{\"name\":\"Mycopathologia\",\"volume\":\"190 5\",\"pages\":\"66\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mycopathologia\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1007/s11046-025-00977-z\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MYCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycopathologia","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11046-025-00977-z","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

慢性角化性足癣是一种难治性感染。我们对21例过度角化性足癣患者局部应用1%露立康唑3个月疗程的疗效进行评估。通过显微镜和培养证实了诊断。使用软件程序每月评估病变面积。临床反应从“治愈”到“无变化”分为五类。其中检出1株耐特比萘芬的红恙螨。3个月内平均病变面积明显缩小，平均改善率94.1%±12.7%，治愈率61.9%。每足平均使用量为27.5±9.7 g /月。耐药病例局部应用露立康唑治疗后部分好转，口服非曲康唑治疗成功。这些结果表明，1%的局部露立康唑治疗过度角化性足癣是有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Topical Luliconazole Treatment for Hyperkeratotic Tinea Pedis.

Chronic hyperkeratotic tinea pedis is a treatment-resistant infection. We evaluated the efficacy of a 3-month course of topical 1% luliconazole in 21 hyperkeratotic tinea pedis patients. The diagnosis was confirmed through microscopy and culture. The lesion area was assessed monthly using a software program. Clinical responses were classified into five categories from "cured" to "no change." Among the isolates, one terbinafine-resistant T. rubrum strain was detected. The mean lesion area decreased significantly over 3 months, with an average improvement rate of 94.1% ± 12.7% and a cure rate of 61.9%. The mean amount of luliconazole used per foot was 27.5 ± 9.7 g monthly. The resistant case showed a partial improvement with topical luliconazole and was successfully treated with oral fosravuconazole. These findings suggest that 1% topical luliconazole is effective for treating hyperkeratotic tinea pedis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Mycopathologia 生物-真菌学

CiteScore

6.80

自引率

3.60%

发文量

审稿时长

3 months

期刊介绍： Mycopathologia is an official journal of the International Union of Microbiological Societies (IUMS). Mycopathologia was founded in 1938 with the mission to ‘diffuse the understanding of fungal diseases in man and animals among mycologists’. Many of the milestones discoveries in the field of medical mycology have been communicated through the pages of this journal. Mycopathologia covers a diverse, interdisciplinary range of topics that is unique in breadth and depth. The journal publishes peer-reviewed, original articles highlighting important developments concerning medically important fungi and fungal diseases. The journal highlights important developments in fungal systematics and taxonomy, laboratory diagnosis of fungal infections, antifungal drugs, clinical presentation and treatment, and epidemiology of fungal diseases globally. Timely opinion articles, mini-reviews, and other communications are usually invited at the discretion of the editorial board. Unique case reports highlighting unprecedented progress in the diagnosis and treatment of fungal infections, are published in every issue of the journal. MycopathologiaIMAGE is another regular feature for a brief clinical report of potential interest to a mixed audience of physicians and laboratory scientists. MycopathologiaGENOME is designed for the rapid publication of new genomes of human and animal pathogenic fungi using a checklist-based, standardized format.